Abstract
Dominant pathogenic variants in ATP1A3 can occur anywhere in the coding sequence and can cause a wide range of clinical presentations. A practical problem is that sequencing services use one of 3 different mRNA transcripts with different lengths to number the candidate variants. Genetic reports often identify an ATP1A3 variant as a VUS when it is actually well validated. Only 1 transcript, the MANE Select transcript that encodes a protein of 1, 013 amino acids, is well supported by evidence. Misidentification of variants in ATP1A3 is disadvantageous when it prevents a confident diagnosis. We illustrate the differences among the 3 transcripts and their merits. Sequencing services should use the MANE Select transcript.
| Original language | English |
|---|---|
| Article number | e200320 |
| Journal | Neurology: Genetics |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2025 |
Fingerprint
Dive into the research topics of 'Pathogenic Variants in ATP1A3: Why Is There So Much Confusion?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver